Rinaldo C R, Liebmann J M, Huang X L, Fan Z, Al-Shboul Q, McMahon D K, Day R D, Riddler S A, Mellors J W
Deptartment of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA. rinaldo+@pitt.edu
J Infect Dis. 1999 Feb;179(2):329-36. doi: 10.1086/314599.
CD4 T cell responses were studied for >2 years in 27 zidovudine-experienced patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who received triple combination drug therapy with indinavir, zidovudine and lamivudine or zidovudine plus lamivudine or zidovudine alone for 24-42 weeks before switching to the three-drug therapy. Subjects initially given the three drugs had viremia suppressed to undetectable levels and increases in T cell proliferative and cytokine responses to microbial antigens through 2 years of follow-up. Patients receiving the triple-drug therapy after either indinavir or zidovudine-lamivudine treatment had similar increases in T cell responses only if they also had suppression of virus load. CD4 T cell reactivity to HIV-1 antigens was not restored. Prolonged indinavir-zidovudine-lamivudine treatment has significant but incomplete enhancing effects on CD4 T cell reactivity, which could be important in host control of microbial and persistent HIV-1 infections.
对27例有齐多夫定治疗史的晚期人类免疫缺陷病毒1型（HIV-1）感染患者的CD4 T细胞反应进行了2年多的研究，这些患者在改用三联药物治疗前，接受了茚地那韦、齐多夫定和拉米夫定或齐多夫定加拉米夫定或单独使用齐多夫定的三联联合药物治疗24至42周。最初接受三种药物治疗的受试者在长达2年的随访中，病毒血症被抑制到检测不到的水平，并且对微生物抗原的T细胞增殖和细胞因子反应有所增加。在茚地那韦或齐多夫定-拉米夫定治疗后接受三联药物治疗的患者，只有在病毒载量也得到抑制的情况下，T细胞反应才会有类似的增加。CD4 T细胞对HIV-1抗原的反应性未恢复。茚地那韦-齐多夫定-拉米夫定的长期治疗对CD4 T细胞反应性有显著但不完全的增强作用，这在宿主控制微生物和持续性HIV-1感染中可能很重要。
